Drug Trial Radar · NCT01928433
Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Last checked: Nov 19, 2026Latest source record: Jun 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Dec 2012
Primary completion
Jun 2014
Study completion Oct 2015
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the microbiological and clinical outcome of treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator. Finafloxacin shows increased activity in an acidic environment which is associated with indications such as uUTI and cUTI. Given the acidic pH of urine and concentration of finafloxacin excreted via the urinary tract in humans it should be proven if the finafloxacin treatments offer significant advantages over the currently available treatments for UTI.
Conditions
- Urinary Tract Infections
- Acute Pyelonephritis
Interventions
Finafloxacin 800 mg i.v. once dailyDrug
Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Finafloxacin placebo i.v. once dailyDrug
Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Finafloxacin 800 mg tablets once dailyDrug
Administered as four 200 mg tablets
Finafloxacin placebo tablets once dailyDrug
Administered as four tablets
Ciprofloxacin 400 mg i.v. twice dailyDrug
Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Ciprofloxacin placebo i.v. twice dailyDrug
Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Ciprofloxacin 500 mg oral twice dailyDrug
Administered as two 250 mg capsules.
Ciprofloxacin placebo oral twice dailyDrug
Administered as two capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical and Microbiological ResponseTime frame: Day 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Giessen, Klinik für Urologie, Kinderurologie und Andrologie
Giessen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.